Hence, the aims of the present study were to assess the prevalence of T2DM in HeFH patients of the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, and evaluate the impact of mutations in the LDLR, APOB and PCSK9 genes, baseline LDL cholesterol concentration and duration of statin treatment on T2DM prevalence in this population. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.